Literature DB >> 18097881

Toll-like receptor pathway gene expression is associated with human immunodeficiency virus-associated neurodegeneration.

Shahid Salaria1, Haleh Badkoobehi, Edward Rockenstein, Leslie Crews, Gursharan Chana, Eliezer Masliah, Ian P Everall.   

Abstract

The innate immune system is a significant component of the brain's defense against infection, especially as the blood-brain barrier restricts access of the members of the adaptive immune system, such as T and B cells. The innate immune system includes Toll-like receptors (TLRs) that recognize pathogen-associated molecular patterns. Within the central nervous system, they are expressed on glial cells and their expression can be modulated by pathological states. Although their function is to recognize foreign pathogens and stimulate a protective immune response through the production of cytokines and interferons, there is emerging evidence that activation of these receptors can result in neurodegeneration. In the current study, the authors assessed the expression of TLR-related genes, using a customized Superarray gene chip, and correlated the expression findings with indices of neurodegeneration. We found that, using a stringent threshold for statistical significance to overcome the potential problem of multiple statistical testing, there were significant correlations between the expression of nine TLR-related genes and reduction in dendritic and synaptic staining. Two of these genes, TLR4 and SIGIRR, were validated by quantitative real-time polymerase chain reaction. Additionally, the authors demonstrated in vitro at the protein level that human primary astrocytes exposed to the toxic human immunodeficiency virus (HIV) envelope protein gp120 had a significant increase in TLR4 protein expression. In conclusion, these findings indicate that TLR-related gene expression may contribute to the development of HIV-related neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18097881     DOI: 10.1080/13550280701558616

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  33 in total

1.  Expression of JNK cascade scaffold protein JSAP1 in the mouse nervous system.

Authors:  M Akechi; M Ito; K Uemura; N Takamatsu; S Yamashita; K Uchiyama; K Yoshioka; T Shiba
Journal:  Neurosci Res       Date:  2001-04       Impact factor: 3.304

Review 2.  Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases.

Authors:  Christophe Bonny; Tiziana Borsello; Azel Zine
Journal:  Rev Neurosci       Date:  2005       Impact factor: 4.353

3.  Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center.

Authors:  I P Everall; R K Heaton; T D Marcotte; R J Ellis; J A McCutchan; J H Atkinson; I Grant; M Mallory; E Masliah
Journal:  Brain Pathol       Date:  1999-04       Impact factor: 6.508

4.  Double-stranded RNA signals antiviral and inflammatory programs and dysfunctional glutamate transport in TLR3-expressing astrocytes.

Authors:  Philip O Scumpia; Kindra M Kelly; Westley H Reeves; Bruce R Stevens
Journal:  Glia       Date:  2005-11-01       Impact factor: 7.452

5.  Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis.

Authors:  Eliezer Masliah; Eleanor S Roberts; Dianne Langford; Ian Everall; Leslie Crews; Anthony Adame; Edward Rockenstein; Howard S Fox
Journal:  J Neuroimmunol       Date:  2004-12       Impact factor: 3.478

6.  Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9).

Authors:  Asparouh I Iliev; Argyrios K Stringaris; Roland Nau; Harald Neumann
Journal:  FASEB J       Date:  2003-12-19       Impact factor: 5.191

7.  Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

Authors:  Ozlem Equils; Alan Shapiro; Zeynep Madak; Chunren Liu; Daning Lu
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 8.  Peptidoglycan recognition proteins: on and off switches for innate immunity.

Authors:  Håkan Steiner
Journal:  Immunol Rev       Date:  2004-04       Impact factor: 12.988

9.  Differential regulation of Toll-like receptor mRNAs in experimental murine central nervous system infections.

Authors:  Tobias Böttcher; Matthias von Mering; Sandra Ebert; Uta Meyding-Lamadé; Ulrich Kuhnt; Joachim Gerber; Roland Nau
Journal:  Neurosci Lett       Date:  2003-06-19       Impact factor: 3.046

10.  Surface CD4 expression modulated by a cellular factor induced by HIV type 1 infection.

Authors:  Dennis Sheeter; Pinyi Du; Steffney Rought; Douglas Richman; Jacques Corbeil
Journal:  AIDS Res Hum Retroviruses       Date:  2003-02       Impact factor: 2.205

View more
  11 in total

1.  The impact of glial activation in the aging brain.

Authors:  Aileen M Lynch; Kevin J Murphy; Brian F Deighan; Julie-Ann O'Reilly; Yuri K Gun'ko; Thelma R Cowley; Rodrigo E Gonzalez-Reyes; Marina A Lynch
Journal:  Aging Dis       Date:  2010-09-04       Impact factor: 6.745

Review 2.  Toll-like receptor signaling in neural plasticity and disease.

Authors:  Eitan Okun; Kathleen J Griffioen; Mark P Mattson
Journal:  Trends Neurosci       Date:  2011-03-16       Impact factor: 13.837

3.  Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and morphine.

Authors:  Nazira El-Hage; Elizabeth M Podhaizer; Jamie Sturgill; Kurt F Hauser
Journal:  Immunol Invest       Date:  2011-03-22       Impact factor: 3.657

Review 4.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

Review 5.  Neurodegeneration and ageing in the HAART era.

Authors:  Bruce J Brew; S M Crowe; A Landay; Lucette A Cysique; Gilles Guillemin
Journal:  J Neuroimmune Pharmacol       Date:  2008-12-06       Impact factor: 4.147

6.  Form follows function: astrocyte morphology and immune dysfunction in SIV neuroAIDS.

Authors:  Kim M Lee; Kevin B Chiu; Nicole A Renner; Hope A Sansing; Peter J Didier; Andrew G MacLean
Journal:  J Neurovirol       Date:  2014-06-27       Impact factor: 2.643

Review 7.  HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches.

Authors:  Marcus Kaul
Journal:  Curr Opin Neurol       Date:  2009-06       Impact factor: 5.710

Review 8.  Common transcriptional signatures in brain tissue from patients with HIV-associated neurocognitive disorders, Alzheimer's disease, and Multiple Sclerosis.

Authors:  Alejandra Borjabad; David J Volsky
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-12       Impact factor: 4.147

9.  Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer's disease.

Authors:  Andrew J Levine; Jeremy A Miller; Paul Shapshak; Benjamin Gelman; Elyse J Singer; Charles H Hinkin; Deborah Commins; Susan Morgello; Igor Grant; Steve Horvath
Journal:  BMC Med Genomics       Date:  2013-02-13       Impact factor: 3.063

Review 10.  Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders.

Authors:  Alejandra Borjabad; Andrew I Brooks; David J Volsky
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-21       Impact factor: 7.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.